Merck set to launch new version of fertility pens

EMA approves Merck's GONAL-f prefilled pen 2.0.

“Similarly to the development of the previous version of the prefilled pens, we listened to our patients and healthcare professionals, understanding that the best insights come from the people using and working with our fertility treatment portfolio. Being the world leader in fertility treatment, we were carefully assessing their needs, using our knowledge gained from working with the community for many decades to identify new solutions,” said Luciano Rossetti, Head of Global Research and Development, at the biopharma business of Merck. “The new GONAL-f prefilled pen was developed with a focus on improving the patient treatment experience using the pen. This ensures that the pen is simple to handle so that patients feel confident they are getting the highest possible chance to become pregnant.”

Since its launch 20 years ago, more than two million babies have been brought to the world with the help of GONAL-f. The prefilled pen provides patients with a simplified self-administrating injection platform for Merck’s gonadotropins. Its enhanced design has made the new GONAL-f prefilled pen easier to handle with a larger display window that improves the readability of the dosage information.

Together with a graduated scale on a transparent cartridge, these new features provide increased clarity for the patient, reassuring them that the correct preset dose has been administered. These enhanced qualities add to the strong original key features of the prefilled pen: dosing accuracy and the ability to improve treatment outcomes by enabling individualized dosing.

With a high need for specialized and innovative solutions, patients suffering from infertility is one of Merck’s core focus areas in healthcare. The new GONAL-f prefilled pen is the most recent addition to our growing portfolio to support fertility treatment. Using its long heritage and in-depth knowledge in the area, Merck continues to drive innovation to help further improve fertility treatment outcomes.